Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $93,744.09 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 4,117 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $22.77, for a total transaction of $93,744.09. Following the sale, the insider owned 77,484 shares of the company’s stock, valued at $1,764,310.68. This trade represents a 5.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ KMTS traded up $1.16 during trading hours on Monday, hitting $23.99. 373,728 shares of the company’s stock were exchanged, compared to its average volume of 404,856. The company’s 50-day moving average price is $22.62 and its 200-day moving average price is $22.48. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. On average, sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Oppenheimer started coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. BTIG Research upped their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $27.83.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies during the fourth quarter valued at $31,000. Russell Investments Group Ltd. grew its holdings in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies during the 4th quarter valued at about $72,000. Finally, Brown Brothers Harriman & Co. boosted its position in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.